drugset / Trial / NCT03384589
CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study
Phase 2/3
Completed
248 enrolled
University of British Columbia
Alberta Children's Hospital · collabCanadian Immunization Research Network · collabCanadian Institutes of Health Research (CIHR) · collabIWK Health Centre · collabUniversity of Calgary · collabUniversité de Montréal · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This study is assessing if a reduced dosing schedule (1+1) of the 13-valent pneumococcal conjugate vaccine (PCV13) is non-inferior to the currently used schedule used in most of Canada.The vaccine is currently usually given as 3 doses at 2, 4 and 12 months of age. This study aims to find out if it is possible to achieve the same protection using just 2 doses, at 2 and 12 months.
Timeline
- Start
- 2018-08-23
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Prevnar 13 | Vaccine | 0.5 ml | Intramuscular |